Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0463 | 1 | 1 |
Leishmania major | mitochondrial DNA polymerase beta | 0.0306 | 0.5609 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0306 | 0.5609 | 1 |
Schistosoma mansoni | inhibitor of apoptosis (iap) domain family member | 0.0463 | 1 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0161 | 0.1549 | 0.5 |
Trypanosoma brucei | mitochondrial DNA polymerase beta | 0.0306 | 0.5609 | 1 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0106 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0463 | 1 | 1 |
Schistosoma mansoni | inhibitor of apoptosis protein | 0.0463 | 1 | 1 |
Echinococcus multilocularis | inhibitor of apoptosis protein | 0.0463 | 1 | 1 |
Echinococcus granulosus | inhibitor of apoptosis protein | 0.0463 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0463 | 1 | 1 |
Onchocerca volvulus | Deterin homolog | 0.0463 | 1 | 1 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0106 | 0 | 0.5 |
Echinococcus multilocularis | baculoviral IAP repeat containing protein | 0.0463 | 1 | 1 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0106 | 0 | 0.5 |
Giardia lamblia | Glycogen phosphorylase | 0.0106 | 0 | 0.5 |
Onchocerca volvulus | 0.0463 | 1 | 1 | |
Mycobacterium ulcerans | hypothetical protein | 0.0161 | 0.1549 | 0.5 |
Echinococcus granulosus | baculoviral IAP repeat containing protein | 0.0463 | 1 | 1 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0106 | 0 | 0.5 |
Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0463 | 1 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0306 | 0.5609 | 1 |
Chlamydia trachomatis | glycogen phosphorylase | 0.0106 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.